Group items tagged

Emerging players with potentially strong product portfolio is expected to capture the global Xerosis treatment market. It is essential for the marketers to design effective counter-strategies to gain competitive advantage. A promising pipeline indicates mergers and acquisitions. Devising corrective measures for pipeline projects would also require an in-depth understanding of the Xerosis pipeline depth and focus of indication therapeutics.

Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2015', provides an overview of the Respiratory Syncytial Virus (RSV) Infections's therapeutic pipeline.

Global Markets Directs, Dengue - Pipeline Review, H1 2014, provides an overview of the Dengues therapeutic pipeline. It also enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

One of the main drivers propelling the growth of the market for drugs used to treat patients with Parkinson's disease is the steadily growing aging population worldwide. This is because the number of patients suffering from Parkinson's disease is increasing owing to the rise in aging population both in the developing as well as developed nations. One of the major challenges to market growth is the weak pipeline landscape. Most products in the pipeline lack molecules that can potentially achieve blockbuster status in the near future.

Prospective partners with the most attractive projects are expected to enhance and expand business potential and scope for uterine cancer therapy globally. Marketers are developing and designing in-licensing and out-licensing strategies based on the identification of emerging players with potentially strong product portfolio. They are also designing effective counter-strategies to gain competitive advantage.

An in-depth analysis of the diverse types of therapeutics under development for T-Cell Lymphomas and identification of emerging players with potentially strong product portfolio assists marketers design effective counter-strategies to gain competitive advantage. Latest updates provide insights into the most attractive projects with emerging opportunities to enhance and expand business potential and scope.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Analysis of leukemia business development enables tracking cutting edge companies, therapies and new technologies. Analysis of key areas of pharmaceutical R&D helps identify emerging leukemia products. The tool is designed in a way to assist in finding right partners, optimizing licensing deals and choosing projects that give the best competitive advantage.

Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012, comprising Aventis Taxotere (docetaxel), Bristol-Myers Squibbs Paraplatin (carboplatin) and Eli Lillys Gemzar (gemcitabine). The third-generation chemotherapeutic agents have expanded the therapeutic options in the treatment of advanced lung cancer. However, despite their contributions, science has reached a therapeutic plateau.

The launch of Protease Inhibitors (PIs) accelerated the pace of innovation and impressive Sustained Virologic Response (SVR) rates by oral IFN free drug combinations. Freedom from IFN, treating all genotypes and vaccines could bring a sea of change in the HCV therapy class area in the future. Roche set the trend with the acquisition of Anadys for total of USD 230 mn followed by GILD buying VRUS for USD 11 bn, Bristol-Myers Squibb (BMY) acquiring Inhibitex for USD 2.5 bn, VRTX acquiring Virochem in 2009 for USD 375 mn, In-licensed Alios VX-135 in 2012 for total of USD 775 mn and Abbott in-licensed Enantas ABT-450 for total of USD 310 mn.

A progress analysis on current and emerging drugs on the peptide drug development the reveals promising investment opportunities. Popular products included in the package are Cancer Peptides: From First-in-Class to Best-in-Class; and Peptides in Oncology Drug Pipeline Update 2013.

The competitive landscape of the wound closure devices market to 2019 unveils emerging market opportunities for active players in the market. Identification of key players best positioned to take advantage of the emerging market opportunities wound closure devices market attracts investment. Key wound closure devices market segments include mechanical stapling devices, hemostats, tissue sealants, ligating clips and wound closure strips. Identification of active market players with the most innovative pipelines fosters exploitation opportunities for mergers and acquisitions.

Historic and forecast data for the production, consumption and reserves of crude oil in Saudi Arabia unfolds a host of opportunities for the various stakeholders in the market. A study of all the major oil fields, refineries, pipelines and storage terminals in the country offer a perspective on the current development status of the sector as well as provides insights on the future prospects of the sector. Companies operating in the sector are constantly undertaking R&D activities and the sector is seeing several mergers and acquisitions, partnerships, private equity and venture capital investments, and IPOs.

With conventional corticosteroid treatment being effective in only 50-60% of patients, development of new treatment options is necessary to cover the unmet needs of the uveitis market. The market is currently dominated by corticosteroid treatment options and off-label immunosuppressive and biologic drugs. Although anterior uveitis patients constitute the major share of patients, except one, all the new treatments in late stage clinical development target the intermediate, posterior and pan uveitis patient segment. Drugs capable of permanently inhibiting ocular inflammation as well as offering an improved safety profile will have a significant impact on the uveitis market.